Spero Therapeutics Reports Significant Financial Turnaround, Advances Tebipenem HBr with June 2026 PDUFA Date, and Concludes SEC Investigation

summarizeSummary

Spero Therapeutics reported a net income of $8.6 million for 2025, a significant turnaround, driven by progress on its lead asset, tebipenem HBr, which now has a PDUFA date of June 18, 2026. The company also received a $25.0 million milestone payment and saw the conclusion of an SEC investigation without enforcement action against the company.

check_boxKey Events

• Financial Turnaround

  Reported a net income of $8.6 million for the fiscal year 2025, a significant improvement from a $68.6 million net loss in 2024.

• Tebipenem HBr Regulatory Progress

  GSK's New Drug Application (NDA) resubmission for tebipenem HBr has been accepted by the FDA, with a PDUFA date set for June 18, 2026.

• Significant Milestone Payment Received

  Received a $25.0 million milestone payment in February 2026 from GSK for the tebipenem HBr NDA filing, with potential for up to $326.0 million in additional commercial and sales milestones.

• SEC Investigation Concluded

  The SEC concluded its investigation into the company without recommending enforcement action against Spero Therapeutics, removing a significant legal overhang.

auto_awesomeAnalysis

Spero Therapeutics' annual 10-K filing reveals a substantial financial turnaround, reporting a net income of $8.6 million for 2025, a significant improvement from the $68.6 million net loss in 2024. This positive financial performance is bolstered by the continued advancement of its lead product candidate, tebipenem HBr, which has a Prescription Drug User Fee Act (PDUFA) date set for June 18, 2026, following GSK's New Drug Application (NDA) resubmission in December 2025. The company also received a $25.0 million milestone payment in February 2026 for the NDA filing, with potential for up to $326.0 million in additional commercial and sales milestones. Furthermore, a major overhang has been removed as the SEC concluded its investigation into the company without recommending enforcement action against Spero Therapeutics. The company has strategically refocused its resources by ceasing development of its SPR206 and SPR720 programs, extending its cash runway into 2028. This comprehensive update signals strong progress on both financial and operational fronts, particularly in de-risking its lead asset and resolving a significant legal matter.